Majority of Patients With Cancer Are Willing To Be Vaccinated Against COVID-19
Results from a cross-sectional survey in France
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib
It is intended for second-line treatment of advanced cholangiocarcinoma with a FGFR2 fusion or rearrangement
FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
Evidence for efficacy is based on the results from the CHECKMATE-9ER study
FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase for Newly Diagnosed Light Chain Amyloidosis
Evidence for efficacy is based on the results from the ANDROMEDA study
Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early Breast Cancer
The Cancer and Aging Research Group-Breast Cancer score was developed and validated to predict grade 3-5 toxicity in elderly patients with stage I-III disease
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas
Evidence for efficacy is based on the results from the DESTINY-Gastric01 study
FDA Approves Crizotinib for Children and Young Adults with Relapsed or Refractory, Systemic ALK-positive Anaplastic Large Cell Lymphoma
The safety and efficacy of crizotinib is not established in older adults with same disease
GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations
The analysis also illustrates differences according to sex and ethnic group
Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients with MSI/dMMR Stage III Colon Cancer
The ACCENT database analysis supports flouropyrimidine plus oxaliplatin as standard-of-care adjuvant treatment for patients with MSI/dMMR stage III colon cancer
Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast Cancer
The RSClin integrates genomic and clinical features, thereby offering the potential to guide the use of adjuvant chemotherapy with greater precision
Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk of Metachronous Contralateral Testicular Cancer Occurrence
Retrospective study indicates that the age at first testicular cancer diagnosis and treatment intensity influence the second testicular cancer risk
Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in HR-positive, HER2-negative Aromatase Inhibitor Resistant Metastatic Breast Cancer
Head to head comparison demonstrates progression-free survival advantage with chemotherapy over palbociclib plus endocrine therapy